Desbois AC, Cacoub P. Systemic sclerosis: an update in 2016. Autoimmun Rev. 2016;15(5):417–26.
Article
PubMed
Google Scholar
Walker UA, Tyndall A, Czirják L, Denton C, Farge-Bancel D, Kowal-Bielecka O, Müller-Ladner U, Bocelli-Tyndall C, Matucci-Cerinic M. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR scleroderma trials and research group database. Ann Rheum Dis. 2007;66(6):754–63.
Article
CAS
PubMed
PubMed Central
Google Scholar
Mayes MD. The scleroderma book: a guide for patients and families. New York: Oxford University Press; 1999.
Google Scholar
Steen VD. Clinical manifestations of systemic sclerosis. Semin Cutan Med Surg. 1998;17:48–54.
Article
CAS
PubMed
Google Scholar
Connolly MK. Scleroderma. Dermatol Ther. 2001;14:81–94.
Article
Google Scholar
Razykov I, Thombs BD, Hudson M, et al. Prevalence and clinical correlates of pruritus in patients with systemic sclerosis. Arthritis Care Res. 2009;61:1765–70.
Article
Google Scholar
Hebbar M, Gillot JM, Hachulla E, Lassalle P, Hatron PY, Devulder B, Janin A. Early expression of E-selectin, tumor necrosis factor alpha, and mast cell infiltration in the salivary glands of patients with systemic sclerosis. Arthritis Rheum. 1996;39(7):1161–5.
Article
CAS
PubMed
Google Scholar
Hügle T, Hogan V, White KE, van Laar JM. Mast cells are a source of transforming growth factor β in systemic sclerosis. Arthritis Rheum. 2011;63(3):795–9.
Article
PubMed
Google Scholar
Irani AM, Gruber BL, Kaufman LD, Kahaleh MB, Schwartz LB. Mast cell changes in scleroderma. Presence of MCT cells in the skin and evidence of mast cell activation. Arthritis Rheum. 1992;35(8):933–9.
Article
CAS
PubMed
Google Scholar
Akimoto S, Ishikawa O, Igarashi Y, Kurosawa M, Miyachi Y. Dermal mast cells in scleroderma: their skin density, tryptase/chymase phenotypes and degranulation. Br J Dermatol. 1998;138(3):399–406.
Article
CAS
PubMed
Google Scholar
Onishi A, Sugiyama D, Kumagai S, Morinobu A. Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum. 2013;65(7):1913–21.
Article
PubMed
Google Scholar
Olesen AB, Svaerke C, Farkas DK, Sørensen HT. Systemic sclerosis and the risk of cancer: a nationwide population-based cohort study. Br J Dermatol. 2010;163(4):800–6.
Article
CAS
PubMed
Google Scholar
Kuo CF, Luo SF, Yu KH, Chou IJ, Tseng WY, Chang HC, Fang YF, Chiou MJ, See LC. Cancer risk among patients with systemic sclerosis: a nationwide population study in Taiwan. Scand J Rheumatol. 2012;41(1):44–9.
Article
PubMed
Google Scholar
Frigui M, Dupin N, Carlotti A, Bussone G, Pestre V, Charles P, Crabol Y, Bérezné A, Guillevin L, Mouthon L. Telangiectasic mastocytosis with systemic sclerosis. Presse Med. 2013;42(5):902–4.
Article
PubMed
Google Scholar
Bagnato G, Harari S. Cellular interactions in the pathogenesis of interstitial lung diseases. Eur Respir Rev. 2015;24(135):102–14.
Article
PubMed
Google Scholar
Yukawa S, Yamaoka K, Sawamukai N, Shimajiri S, Saito K, Tanaka Y. Involvement of mast cells in systemic sclerosis. Nihon Rinsho Meneki Gakkai Kaishi. 2010;33(2):81–6.
Article
CAS
PubMed
Google Scholar
Yukawa S, Yamaoka K, Sawamukai N, Shimajiri S, Kubo S, Miyagawa I, Sonomoto K, Saito K, Tanaka Y. Dermal mast cell density in fingers reflects severity of skin sclerosis in systemic sclerosis. Mod Rheumatol. 2013;23(6):1151–7.
Article
CAS
PubMed
Google Scholar
Akimoto S, Ishikawa O, Igarashi Y, Kurosawa M, Miyachi Y. Dermal mast cells in scleroderma: their skin density, tryptase/chymase phenotypes and degranulation. Br J Dermatol. 1998;138(3):399–406.
Article
CAS
PubMed
Google Scholar
Hügle T, Hogan V, White KE, van Laar JM. Mast cells are a source of transforming growth factor β in systemic sclerosis. Arthritis Rheum. 2011;63(3):795–9.
Article
PubMed
Google Scholar
Hügle T. Beyond allergy: the role of mast cells in fibrosis. Swiss Med Wkly. 2014;3(144):w13999.
Google Scholar
Vega-Ruiz A, Cortes JE, Sever M, Manshouri T, Quintás-Cardama A, Luthra R, Kantarjian HM, Verstovsek S. Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. Leuk Res. 2009;33(11):1481–4.
Article
CAS
PubMed
PubMed Central
Google Scholar
Denton CP, Merkel PA, Furst DE, Khanna D, Emery P, Hsu VM, Silliman N, Streisand J, Powell J, Akesson A, Coppock J, et al. Cat-192 Study Group; Scleroderma Clinical Trials Consortium. Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum. 2007;56(1):323–33.
Article
CAS
PubMed
Google Scholar
Akhmetshina A, Venalis P, Dees C, Busch N, Zwerina J, Schett G, Distler O, Distler JH. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum. 2009;60(1):219–24.
Article
CAS
PubMed
Google Scholar
Fraticelli P, Gabrielli B, Pomponio G, Valentini G, Bosello S, Riboldi P, Gerosa M, Faggioli P, Giacomelli R, Del Papa N, Gerli R, Lunardi C, Bombardieri S, Malorni W, Corvetta A, Gabrielli A, Moroncini G. Imatinib in Scleroderma Italian Study Group. Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study. Arthritis Res Ther. 2014;16(4):R144. doi:10.1186/ar4606.
Article
PubMed
PubMed Central
Google Scholar